Why is NPCE down?
Down 39% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
- Neuropace fell 39% from Nov 9 to Nov 20. It fell 37% on Nov 13 alone,
−3Long-term trend
Down 39% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
−3Long-term trend
NPCE's Quality Score fell 3 points on Fri, Nov 20, to -3. Its quiet day ended (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 12.3% a day with no profit behind it |
| Latest filing | 8-K, Nov 12 |
After its last 4 reports it closed -9.9% on average, higher 2 of 4 times.
NPCE is #73 of 86 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 73 |
Expected to report Tue Mar 2, after the close (in 101 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $23.1M, 1% less than a year ago.
“The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”
NPCE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Its share count grew 10% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -48.0% | -37.1% | -32.3% |
| Aug 11, 2026 | -5.9% | -3.3% | -3.9% |
| May 12, 2026 | -6.1% | +0.1% | +0.3% |
Sales grew every year from 2020 to 2025, to $100M. It lost money in each of the six years.
RSI 25.6, MACD below signal, below both averages. Not scored.
3 insiders bought $302K across 3 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NPCE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
“Our industry is competitive and has been evolving rapidly with the introduction of new products and technologies as well as the market activities of industry participants.”
NPCE scores -3 today, which Breakaway calls Poor. It is #73 of 86 in Medical Devices by Quality Score, with 0 of 14 chart checks firing. Down 39% from Nov 9 to Nov 20 while the S&P 500 fell 8%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NPCE scores -3 today, which Breakaway calls Poor (below zero). That is #73 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NPCE's -3.
3 insiders bought $302K across 3 filings in the last 6 months. No open-market sales on record. The newest is R. Scott Huennekens, Director, who bought $104K on Nov 18. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.